Impact of vaccination on infection or death from COVID-19 in individuals with laboratory-confirmed cases: Case-control study
The objective of this study is to estimate the effectiveness of COVID-19 vaccines in people treated within the social security system whose vaccination status was reported to the epidemiological surveillance system. Case-control study. This was a case-control study conducted. The records of individu...
Gespeichert in:
| Veröffentlicht in: | PloS one 2023-08, Vol.18 (8), p.e0265698-e0265698 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0265698 |
|---|---|
| container_issue | 8 |
| container_start_page | e0265698 |
| container_title | PloS one |
| container_volume | 18 |
| creator | Hernández Bautista, Porfirio Felipe Grajales Muñiz, Concepción Cabrera Gaytán, David Alejandro Rojas Mendoza, Teresita Vallejos Parás, Alfonso Santacruz Tinoco, Clara Esperanza Alvarado Yaah, Julio Elias Anguiano Hernández, Yu Mei Sandoval Gutiérrez, Nancy Jaimes Betancourt, Leticia |
| description | The objective of this study is to estimate the effectiveness of COVID-19 vaccines in people treated within the social security system whose vaccination status was reported to the epidemiological surveillance system.
Case-control study.
This was a case-control study conducted. The records of individuals with suspected cases of COVID-19 registered in the epidemiological surveillance system between February 1 and June 30, 2021, were studied. RT-qPCR was performed to determine SARS-CoV-2 infection; those with a positive result were considered cases, and those with a negative result were considered controls. The ratio between cases and controls was 1:1.3. The crude and adjusted vaccine effectiveness was considered the prevention of symptomatic infection and death and calculated as the difference between the dose and the risk, with a survival analysis among vaccinated people.
A total of 94,416 individuals were included, of whom 40,192 were considered cases and 54,224 controls; 3,781 (4.00%) had been vaccinated against COVID-19. Vaccination also proved to be a protective factor against COVID-19, especially in the population who received a second dose (OR = 0.31; 95% CI 0.28-0.35). With the application of the vaccine, there was a protective effect against mortality (OR = 0.76; 95% CI 0.66-0.87). Disease prevention was higher for the BNT162-2 mRNA vaccine (82%) followed by the ChAdOx1 vaccine (33%). In the survival analysis, vaccination provided a protective effect.
There was a positive impact of vaccines for the prevention of symptomatic COVID-19, with a second dose generating greater efficacy and a reduction in deaths. |
| doi_str_mv | 10.1371/journal.pone.0265698 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2845498365</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A759478828</galeid><sourcerecordid>A759478828</sourcerecordid><originalsourceid>FETCH-LOGICAL-c627t-3c54add64cecd5df4b8868cb9873e5846f6e8f052e7cc4f3c202e22c58269c463</originalsourceid><addsrcrecordid>eNqNkluL1DAUx4so7rr6DUQLguhDxzS3Jr7IMt4GFga87GvIpMlMlrQZk3Z2B_zwpk53mco-SAK5_f4nh3P-Wfa8BLMSVeW7K9-HVrrZ1rd6BiAllLMH2WnJESwoBOjh0f4kexLjFQAEMUofZyeoIohQjE-z34tmK1WXe5PvpFK2lZ31bZ6mbY1Wh0PIay27TW6Cb_L58nLxsSh5AtKs7c7WvXQxv7aJcHLlg-x82BfKt8aGRte5klHH9_k8LcNtF7zLY9fX-6fZI5Ok-tm4nmU_P3_6Mf9aXCy_LObnF4WisOoKpAiWdU2x0qomtcErxihTK84qpAnD1FDNDCBQV0phgxQEUEOoCIOUK0zRWfbyEHfrfBRj4aKADBPMGaIkER9Gol-llJVOWUontsE2MuyFl1ZMX1q7EWu_EyVAnFdVmSK8GSME_6vXsRONjUo7J1vt-7-fUY4A4EM6r_5B709ppNbSaZG64dPHaggqzivCccUYZIma3UOlUevGpmJrY9P9RPB2Ihgaom-6texjFIvv3_6fXV5O2ddH7EZL122id_3goDgF8QFUwccYtLmrcgnE4OzbaojB2WJ0dpK9OO7QnejWyugPBi303A</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2845498365</pqid></control><display><type>article</type><title>Impact of vaccination on infection or death from COVID-19 in individuals with laboratory-confirmed cases: Case-control study</title><source>DOAJ Directory of Open Access Journals</source><source>Public Library of Science (PLoS)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Hernández Bautista, Porfirio Felipe ; Grajales Muñiz, Concepción ; Cabrera Gaytán, David Alejandro ; Rojas Mendoza, Teresita ; Vallejos Parás, Alfonso ; Santacruz Tinoco, Clara Esperanza ; Alvarado Yaah, Julio Elias ; Anguiano Hernández, Yu Mei ; Sandoval Gutiérrez, Nancy ; Jaimes Betancourt, Leticia</creator><contributor>Aboelhadid, Shawky M</contributor><creatorcontrib>Hernández Bautista, Porfirio Felipe ; Grajales Muñiz, Concepción ; Cabrera Gaytán, David Alejandro ; Rojas Mendoza, Teresita ; Vallejos Parás, Alfonso ; Santacruz Tinoco, Clara Esperanza ; Alvarado Yaah, Julio Elias ; Anguiano Hernández, Yu Mei ; Sandoval Gutiérrez, Nancy ; Jaimes Betancourt, Leticia ; Aboelhadid, Shawky M</creatorcontrib><description>The objective of this study is to estimate the effectiveness of COVID-19 vaccines in people treated within the social security system whose vaccination status was reported to the epidemiological surveillance system.
Case-control study.
This was a case-control study conducted. The records of individuals with suspected cases of COVID-19 registered in the epidemiological surveillance system between February 1 and June 30, 2021, were studied. RT-qPCR was performed to determine SARS-CoV-2 infection; those with a positive result were considered cases, and those with a negative result were considered controls. The ratio between cases and controls was 1:1.3. The crude and adjusted vaccine effectiveness was considered the prevention of symptomatic infection and death and calculated as the difference between the dose and the risk, with a survival analysis among vaccinated people.
A total of 94,416 individuals were included, of whom 40,192 were considered cases and 54,224 controls; 3,781 (4.00%) had been vaccinated against COVID-19. Vaccination also proved to be a protective factor against COVID-19, especially in the population who received a second dose (OR = 0.31; 95% CI 0.28-0.35). With the application of the vaccine, there was a protective effect against mortality (OR = 0.76; 95% CI 0.66-0.87). Disease prevention was higher for the BNT162-2 mRNA vaccine (82%) followed by the ChAdOx1 vaccine (33%). In the survival analysis, vaccination provided a protective effect.
There was a positive impact of vaccines for the prevention of symptomatic COVID-19, with a second dose generating greater efficacy and a reduction in deaths.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0265698</identifier><identifier>PMID: 37535644</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Analysis ; Biology and Life Sciences ; Complications and side effects ; COVID-19 vaccines ; Death ; Disease control ; Effectiveness ; Epidemiology ; Fatalities ; Health aspects ; Infection ; Laboratories ; Medical research ; Medicine and Health Sciences ; mRNA ; Patient outcomes ; People and places ; Prevention ; Risk factors ; Security systems ; Severe acute respiratory syndrome coronavirus 2 ; Social security ; Surveillance systems ; Survival ; Vaccination ; Vaccine efficacy ; Vaccines ; Viral diseases</subject><ispartof>PloS one, 2023-08, Vol.18 (8), p.e0265698-e0265698</ispartof><rights>Copyright: © 2023 Hernández Bautista et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</rights><rights>COPYRIGHT 2023 Public Library of Science</rights><rights>2023 Hernández Bautista et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 Hernández Bautista et al 2023 Hernández Bautista et al</rights><rights>2023 Hernández Bautista et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c627t-3c54add64cecd5df4b8868cb9873e5846f6e8f052e7cc4f3c202e22c58269c463</citedby><cites>FETCH-LOGICAL-c627t-3c54add64cecd5df4b8868cb9873e5846f6e8f052e7cc4f3c202e22c58269c463</cites><orcidid>0000-0001-5314-4786</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10399771/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10399771/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2914,23846,27903,27904,53770,53772,79347,79348</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37535644$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Aboelhadid, Shawky M</contributor><creatorcontrib>Hernández Bautista, Porfirio Felipe</creatorcontrib><creatorcontrib>Grajales Muñiz, Concepción</creatorcontrib><creatorcontrib>Cabrera Gaytán, David Alejandro</creatorcontrib><creatorcontrib>Rojas Mendoza, Teresita</creatorcontrib><creatorcontrib>Vallejos Parás, Alfonso</creatorcontrib><creatorcontrib>Santacruz Tinoco, Clara Esperanza</creatorcontrib><creatorcontrib>Alvarado Yaah, Julio Elias</creatorcontrib><creatorcontrib>Anguiano Hernández, Yu Mei</creatorcontrib><creatorcontrib>Sandoval Gutiérrez, Nancy</creatorcontrib><creatorcontrib>Jaimes Betancourt, Leticia</creatorcontrib><title>Impact of vaccination on infection or death from COVID-19 in individuals with laboratory-confirmed cases: Case-control study</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>The objective of this study is to estimate the effectiveness of COVID-19 vaccines in people treated within the social security system whose vaccination status was reported to the epidemiological surveillance system.
Case-control study.
This was a case-control study conducted. The records of individuals with suspected cases of COVID-19 registered in the epidemiological surveillance system between February 1 and June 30, 2021, were studied. RT-qPCR was performed to determine SARS-CoV-2 infection; those with a positive result were considered cases, and those with a negative result were considered controls. The ratio between cases and controls was 1:1.3. The crude and adjusted vaccine effectiveness was considered the prevention of symptomatic infection and death and calculated as the difference between the dose and the risk, with a survival analysis among vaccinated people.
A total of 94,416 individuals were included, of whom 40,192 were considered cases and 54,224 controls; 3,781 (4.00%) had been vaccinated against COVID-19. Vaccination also proved to be a protective factor against COVID-19, especially in the population who received a second dose (OR = 0.31; 95% CI 0.28-0.35). With the application of the vaccine, there was a protective effect against mortality (OR = 0.76; 95% CI 0.66-0.87). Disease prevention was higher for the BNT162-2 mRNA vaccine (82%) followed by the ChAdOx1 vaccine (33%). In the survival analysis, vaccination provided a protective effect.
There was a positive impact of vaccines for the prevention of symptomatic COVID-19, with a second dose generating greater efficacy and a reduction in deaths.</description><subject>Analysis</subject><subject>Biology and Life Sciences</subject><subject>Complications and side effects</subject><subject>COVID-19 vaccines</subject><subject>Death</subject><subject>Disease control</subject><subject>Effectiveness</subject><subject>Epidemiology</subject><subject>Fatalities</subject><subject>Health aspects</subject><subject>Infection</subject><subject>Laboratories</subject><subject>Medical research</subject><subject>Medicine and Health Sciences</subject><subject>mRNA</subject><subject>Patient outcomes</subject><subject>People and places</subject><subject>Prevention</subject><subject>Risk factors</subject><subject>Security systems</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Social security</subject><subject>Surveillance systems</subject><subject>Survival</subject><subject>Vaccination</subject><subject>Vaccine efficacy</subject><subject>Vaccines</subject><subject>Viral diseases</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNkluL1DAUx4so7rr6DUQLguhDxzS3Jr7IMt4GFga87GvIpMlMlrQZk3Z2B_zwpk53mco-SAK5_f4nh3P-Wfa8BLMSVeW7K9-HVrrZ1rd6BiAllLMH2WnJESwoBOjh0f4kexLjFQAEMUofZyeoIohQjE-z34tmK1WXe5PvpFK2lZ31bZ6mbY1Wh0PIay27TW6Cb_L58nLxsSh5AtKs7c7WvXQxv7aJcHLlg-x82BfKt8aGRte5klHH9_k8LcNtF7zLY9fX-6fZI5Ok-tm4nmU_P3_6Mf9aXCy_LObnF4WisOoKpAiWdU2x0qomtcErxihTK84qpAnD1FDNDCBQV0phgxQEUEOoCIOUK0zRWfbyEHfrfBRj4aKADBPMGaIkER9Gol-llJVOWUontsE2MuyFl1ZMX1q7EWu_EyVAnFdVmSK8GSME_6vXsRONjUo7J1vt-7-fUY4A4EM6r_5B709ppNbSaZG64dPHaggqzivCccUYZIma3UOlUevGpmJrY9P9RPB2Ihgaom-6texjFIvv3_6fXV5O2ddH7EZL122id_3goDgF8QFUwccYtLmrcgnE4OzbaojB2WJ0dpK9OO7QnejWyugPBi303A</recordid><startdate>20230803</startdate><enddate>20230803</enddate><creator>Hernández Bautista, Porfirio Felipe</creator><creator>Grajales Muñiz, Concepción</creator><creator>Cabrera Gaytán, David Alejandro</creator><creator>Rojas Mendoza, Teresita</creator><creator>Vallejos Parás, Alfonso</creator><creator>Santacruz Tinoco, Clara Esperanza</creator><creator>Alvarado Yaah, Julio Elias</creator><creator>Anguiano Hernández, Yu Mei</creator><creator>Sandoval Gutiérrez, Nancy</creator><creator>Jaimes Betancourt, Leticia</creator><general>Public Library of Science</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>COVID</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-5314-4786</orcidid></search><sort><creationdate>20230803</creationdate><title>Impact of vaccination on infection or death from COVID-19 in individuals with laboratory-confirmed cases: Case-control study</title><author>Hernández Bautista, Porfirio Felipe ; Grajales Muñiz, Concepción ; Cabrera Gaytán, David Alejandro ; Rojas Mendoza, Teresita ; Vallejos Parás, Alfonso ; Santacruz Tinoco, Clara Esperanza ; Alvarado Yaah, Julio Elias ; Anguiano Hernández, Yu Mei ; Sandoval Gutiérrez, Nancy ; Jaimes Betancourt, Leticia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c627t-3c54add64cecd5df4b8868cb9873e5846f6e8f052e7cc4f3c202e22c58269c463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Analysis</topic><topic>Biology and Life Sciences</topic><topic>Complications and side effects</topic><topic>COVID-19 vaccines</topic><topic>Death</topic><topic>Disease control</topic><topic>Effectiveness</topic><topic>Epidemiology</topic><topic>Fatalities</topic><topic>Health aspects</topic><topic>Infection</topic><topic>Laboratories</topic><topic>Medical research</topic><topic>Medicine and Health Sciences</topic><topic>mRNA</topic><topic>Patient outcomes</topic><topic>People and places</topic><topic>Prevention</topic><topic>Risk factors</topic><topic>Security systems</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Social security</topic><topic>Surveillance systems</topic><topic>Survival</topic><topic>Vaccination</topic><topic>Vaccine efficacy</topic><topic>Vaccines</topic><topic>Viral diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hernández Bautista, Porfirio Felipe</creatorcontrib><creatorcontrib>Grajales Muñiz, Concepción</creatorcontrib><creatorcontrib>Cabrera Gaytán, David Alejandro</creatorcontrib><creatorcontrib>Rojas Mendoza, Teresita</creatorcontrib><creatorcontrib>Vallejos Parás, Alfonso</creatorcontrib><creatorcontrib>Santacruz Tinoco, Clara Esperanza</creatorcontrib><creatorcontrib>Alvarado Yaah, Julio Elias</creatorcontrib><creatorcontrib>Anguiano Hernández, Yu Mei</creatorcontrib><creatorcontrib>Sandoval Gutiérrez, Nancy</creatorcontrib><creatorcontrib>Jaimes Betancourt, Leticia</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hernández Bautista, Porfirio Felipe</au><au>Grajales Muñiz, Concepción</au><au>Cabrera Gaytán, David Alejandro</au><au>Rojas Mendoza, Teresita</au><au>Vallejos Parás, Alfonso</au><au>Santacruz Tinoco, Clara Esperanza</au><au>Alvarado Yaah, Julio Elias</au><au>Anguiano Hernández, Yu Mei</au><au>Sandoval Gutiérrez, Nancy</au><au>Jaimes Betancourt, Leticia</au><au>Aboelhadid, Shawky M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of vaccination on infection or death from COVID-19 in individuals with laboratory-confirmed cases: Case-control study</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2023-08-03</date><risdate>2023</risdate><volume>18</volume><issue>8</issue><spage>e0265698</spage><epage>e0265698</epage><pages>e0265698-e0265698</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>The objective of this study is to estimate the effectiveness of COVID-19 vaccines in people treated within the social security system whose vaccination status was reported to the epidemiological surveillance system.
Case-control study.
This was a case-control study conducted. The records of individuals with suspected cases of COVID-19 registered in the epidemiological surveillance system between February 1 and June 30, 2021, were studied. RT-qPCR was performed to determine SARS-CoV-2 infection; those with a positive result were considered cases, and those with a negative result were considered controls. The ratio between cases and controls was 1:1.3. The crude and adjusted vaccine effectiveness was considered the prevention of symptomatic infection and death and calculated as the difference between the dose and the risk, with a survival analysis among vaccinated people.
A total of 94,416 individuals were included, of whom 40,192 were considered cases and 54,224 controls; 3,781 (4.00%) had been vaccinated against COVID-19. Vaccination also proved to be a protective factor against COVID-19, especially in the population who received a second dose (OR = 0.31; 95% CI 0.28-0.35). With the application of the vaccine, there was a protective effect against mortality (OR = 0.76; 95% CI 0.66-0.87). Disease prevention was higher for the BNT162-2 mRNA vaccine (82%) followed by the ChAdOx1 vaccine (33%). In the survival analysis, vaccination provided a protective effect.
There was a positive impact of vaccines for the prevention of symptomatic COVID-19, with a second dose generating greater efficacy and a reduction in deaths.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>37535644</pmid><doi>10.1371/journal.pone.0265698</doi><tpages>e0265698</tpages><orcidid>https://orcid.org/0000-0001-5314-4786</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2023-08, Vol.18 (8), p.e0265698-e0265698 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2845498365 |
| source | DOAJ Directory of Open Access Journals; Public Library of Science (PLoS); EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Analysis Biology and Life Sciences Complications and side effects COVID-19 vaccines Death Disease control Effectiveness Epidemiology Fatalities Health aspects Infection Laboratories Medical research Medicine and Health Sciences mRNA Patient outcomes People and places Prevention Risk factors Security systems Severe acute respiratory syndrome coronavirus 2 Social security Surveillance systems Survival Vaccination Vaccine efficacy Vaccines Viral diseases |
| title | Impact of vaccination on infection or death from COVID-19 in individuals with laboratory-confirmed cases: Case-control study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T06%3A10%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20vaccination%20on%20infection%20or%20death%20from%20COVID-19%20in%20individuals%20with%20laboratory-confirmed%20cases:%20Case-control%20study&rft.jtitle=PloS%20one&rft.au=Hern%C3%A1ndez%20Bautista,%20Porfirio%20Felipe&rft.date=2023-08-03&rft.volume=18&rft.issue=8&rft.spage=e0265698&rft.epage=e0265698&rft.pages=e0265698-e0265698&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0265698&rft_dat=%3Cgale_plos_%3EA759478828%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2845498365&rft_id=info:pmid/37535644&rft_galeid=A759478828&rfr_iscdi=true |